Literature DB >> 8361950

Potential antidepressive properties of amantadine, memantine and bifemelane.

E Moryl1, W Danysz, G Quack.   

Abstract

The effects of amantadine, its dimethyl derivative, memantine and the chemically unrelated compound bifemelane were tested for antidepressant activity. Reserpine-induced hypothermia and the forced swim test (Porsolt test) were selected for this purpose. In the former test amantadine and bifemelane but not memantine were effective. In the forced swim test all three agents produced antidepressive-like activity (decreased immobility time), but in case of bifemelane it was less pronounced. The effect in the forced swim test was specific i.e. it was apparently not the result of an increase in general activity as evidenced by control experiments in the open field. The mechanism of amantadine and memantine action may involve indirect dopaminomimetic activity resulting from the blockade of NMDA receptors. However in reserpine-induced hypothermia this explanation is not valid considering the lack of effect of memantine and positive action of amantadine. Hence, amantadine may have an additional central sympathomimetic action that memantine is lacking. Bifemelane antidepressant-like activity might be attributed to an enhancement of noradrenergic transmission. We suggested that amantadine and bifemelane could be particularly useful therapeutically when depressive symptoms are present in patients suffering from Parkinson's disease and dementia.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8361950     DOI: 10.1111/j.1600-0773.1993.tb01351.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  33 in total

Review 1.  New targets for rapid antidepressant action.

Authors:  Rodrigo Machado-Vieira; Ioline D Henter; Carlos A Zarate
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

Review 2.  Modulation of ligand-gated ion channels by antidepressants and antipsychotics.

Authors:  Gerhard Rammes; Rainer Rupprecht
Journal:  Mol Neurobiol       Date:  2007-04       Impact factor: 5.590

Review 3.  The impact of sex as a biological variable in the search for novel antidepressants.

Authors:  Alexia V Williams; Brian C Trainor
Journal:  Front Neuroendocrinol       Date:  2018-05-31       Impact factor: 8.606

4.  Failure of memantine to "reverse" quinpirole-induced hypomotility.

Authors:  Francesca Demontis; Gino Serra
Journal:  World J Psychiatry       Date:  2016-06-22

5.  Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. A quantitative in situ hybridization study.

Authors:  P A Boyer; P Skolnick; L H Fossom
Journal:  J Mol Neurosci       Date:  1998-06       Impact factor: 3.444

6.  6-Hydroxydopamine lesion of locus coeruleus and the antiparkinsonian potential of NMDA-receptor antagonists in rats.

Authors:  N Rückert; M Bubser; W J Schmidt
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

7.  Treatment of Depression in the Patient with Parkinson's Disease.

Authors:  Tiffany W Chow; Jeffrey L Cummings
Journal:  Clin Geriatr       Date:  1998-10

8.  A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.

Authors:  Nancy Diazgranados; Lobna Ibrahim; Nancy E Brutsche; Andrew Newberg; Phillip Kronstein; Sami Khalife; William A Kammerer; Zenaide Quezado; David A Luckenbaugh; Giacomo Salvadore; Rodrigo Machado-Vieira; Husseini K Manji; Carlos A Zarate
Journal:  Arch Gen Psychiatry       Date:  2010-08

Review 9.  Depression in Parkinson's disease. Pharmacological characteristics and treatment.

Authors:  T Tom; J L Cummings
Journal:  Drugs Aging       Date:  1998-01       Impact factor: 3.923

Review 10.  Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Lobna A Ibrahim; Nancy Diaz-Granados; Carlos A Zarate
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.